Eintrag weiter verarbeiten
Verfügbar über Online-Ressource

Mutations in BRCA2 and taxane resistance in prostate cancer

Gespeichert in:

Veröffentlicht in: Scientific reports 7(2017), Artikel-ID 4574
Personen und Körperschaften: Nientiedt, Cathleen (VerfasserIn), Heller, Martina (VerfasserIn), Endris, Volker (VerfasserIn), Volckmar, Anna-Lena (VerfasserIn), Zschäbitz, Stefanie (VerfasserIn), Tapia-Laliena, María Angeles (VerfasserIn), Jäger, Dirk (VerfasserIn), Schirmacher, Peter (VerfasserIn), Sültmann, Holger (VerfasserIn), Stenzinger, Albrecht (VerfasserIn), Hohenfellner, Markus (VerfasserIn), Grüllich, Carsten (VerfasserIn), Duensing, Stefan (VerfasserIn)
Titel: Mutations in BRCA2 and taxane resistance in prostate cancer/ Cathleen Nientiedt, Martina Heller, Volker Endris, Anna-Lena Volckmar, Stefanie Zschäbitz, María A. Tapia-Laliena, Anette Duensing, Dirk Jäger, Peter Schirmacher, Holger Sültmann, Albrecht Stenzinger, Markus Hohenfellner, Carsten Grüllich & Stefan Duensing
Format: E-Book-Kapitel
Sprache: Englisch
veröffentlicht:
4 July 2017
Gesamtaufnahme: : Scientific reports, 7(2017), Artikel-ID 4574
, volume:7
Quelle: Verbunddaten SWB
Lizenzfreie Online-Ressourcen
Details
Zusammenfassung: Mutations in BRCA1 or BRCA2 define a subset of prostate cancer patients. Herein, we address the question whether BRCA1/2 mutations have a predictive impact on chemotherapy with docetaxel, a widely used drug in patients with metastatic castration resistant prostate cancer (mCRPC). Fifty-three men treated with docetaxel for mCRPC were tested for somatic BRCA1/2 mutations of the primary tumor. In a subgroup of patients, BRCA1/2 protein expression was tested as a potential surrogate marker for BRCA1/2 inactivation. Eight of 53 patients (15.1%) harbored a deleterious BRCA2 mutation. No BRCA1 mutation was found. Patients with a BRCA2 mutation showed a response rate of 25% to docetaxel in comparison to 71.1% in men with wildtype BRCA2 (p = 0.019). While the time to develop castration resistance was similar in both subgroups, the overall survival was significantly shorter in patients harboring a BRCA2 mutation. No correlation between the BRCA1/2 protein expression and the response to docetaxel was found. While the presence of a BRCA2 mutation does not preclude a response to docetaxel, there is overall a significant correlation between BRCA2 inactivation and a poor response rate. Our results suggest that a close oncological monitoring of patients with BRCA2 mutations for taxane resistance is warranted.
Beschreibung: Gesehen am 09.10.2018
Im Titel ist "BRCA2" kursiv geschrieben
Umfang: 10
ISSN: 2045-2322
DOI: 10.1038/s41598-017-04897-x